Fluoxetine Lannacher, capsules 20 mg, 20 pcs

1 capsule contains:

fluoxetine hydrochloride 22.4 mg, which corresponds to the fluoxetine content of 20 mg.

Excipients:

lactose,

microcrystalline cellulose,

colloidal silicon dioxide (aerosil),

talc,

magnesium stearate.

Capsule composition:

titanium dioxide,

diamond black,

patent blue,

Ponceau 4R,

azorubin,

gelatin.

Fluoxetine has an antidepressive, anorexigent effect.

Selectively inhibits the reverse capture of serotonin, which leads to an increase in its concentration in the synaptic slit, strengthening and prolonging its action on postsynaptic receptors. By increasing serotonergic transmission, the neural transmitter exchange inhibits the negative feedback mechanism.

With prolonged use, it reduces the activity of 5-HT1 receptors. It also blocks the reuptake of serotonin in platelets. It has a weak effect on the reuptake of norepinephrine and dopamine. It does not have a direct effect on serotonin, m-cholinergic, H1-histamine and alpha-adrenergic receptors. Unlike most antidepressants, it does not cause a decrease in the activity of postsynaptic beta-adrenergic receptors.

Effective for endogenous depression and obsessive-compulsive disorders. Improves mood, reduces tension, anxiety and fear, eliminates dysphoria. It has anorexigic effect, can cause weight loss. In patients with diabetes, it can cause hypoglycemia, and hyperglycemia can cause fluoxetine abolished. The expressed clinical effect in depression occurs after 1-4 weeks of treatment, in obsessive-compulsive disorders - after 5 weeks or more.

When using fluoxetine during pregnancy, there was an increase in the risk of premature birth, developmental abnormalities and low adaptation of newborns (including difficulty breathing, cyanosis, excitability).

There is evidence of fluoxetine efficacy in nutritional disorders (nervous anorexia), alcoholism, anxiety disorders, including sociophobia; diabetic neuropathy, affective, including bipolar, disorders; dysthymia, autism, panic attacks, premenstrual syndrome, narcolepsy, catalepsy, obstructive sleep apnea syndrome, kleptomania, schizophrenia, schizophrenia disorders, etc.

- Depressions of various genesis.
- Nervous bulimia.
- Obsessive-compulsive disorders (obtrusive conditions).

Contraindicated during pregnancy. Breastfeeding should be refused during treatment.

- Hypersensitivity.
- Application of MAO inhibitors (previous 2 weeks).
- Liver and kidney failure (creatinine clearance less than 10 ml/min).
- Epilepsy and convulsive states (in history).
- Suicidal mood.
- Diabetes mellitus.
- Bladder atony.
- Closed-angle glaucoma.
- Prostate hypertrophy.
- Pregnancy.
- Breastfeeding.
With caution:
- Childhood age (safety and effectiveness are not established).
- Myocardial infarction, including history.
- Liver cirrhosis.
- Older age.
- In cardiovascular diseases.
- Insufficiency of liver and/or kidney function.

From the CNS side: dizziness, headache, sleep disorders, increased fatigue, asthenia, tremors, agitation, motor arousal, increased suicidal tendencies, anxiety, mania or hypomania.

From the gastrointestinal tract: decreased appetite, taste disorders, nausea, vomiting, dry mouth or hypersalivation, diarrhea.

Allergic reactions: in the form of skin rash, itching, hives, myalgia, arthralgia, fever.

From the genitourinary system: incontinence or delay in urine, dysmenorrhea, vaginitis, decreased libido, sexual function disorders in men (slowered ejaculation).

Others: increased sweating, tachycardia, visual acuity disorders, weight loss, systemic disorders from the lungs, kidneys or liver, vasculitis.

Incompatible with MAO inhibitors, other antidepressants, furazolidone, procarbazine, because it causes serotonergic syndrome (ash, hyperthermia, muscle rigidity, myoclonus, vegetative lability, hypertensive crisis, arousal, tremors, motor anxiety, seizures, diarrhea, hypomanic condition, delirium, coma. Fatality is possible).

Simultaneous administration with drugs with a high degree of binding to plasma proteins (oral anticoagulants, oral hypoglycemic agents, cardiac glycosides, etc.), mutual displacement from connection with the protein with a change in the concentration of free fraction in the blood is possible, the risk of side effects increases. The risk of bleeding against the background of taking warfarin increases.

It inhibits the biotransformation of drugs metabolized with the participation of CYP2D6 isoenzyme cytochrome P450 (tricyclic antidepressants, dextromethorphan, winblastin, carbamazepine). Lengthens T1/2 diazepam, potentiates the effects of alprazolam.

When taken simultaneously, it changes (increases or decreases) the concentration of lithium in blood plasma, increases the content of phenytoin (before clinical manifestations of its overdose), the level of tricyclic antidepressants (imipramine, desipramin) increases by 2-10 times.

Tryptophan enhances the serotonergic properties of fluoxetine (agitation, motor anxiety, gastrointestinal disorders are possible). Incompatible with ethanol.

Inside. A lasting clinical effect is achieved after 2-3 weeks of treatment, supportive therapy can last up to 6 months.

Depression: 20 mg once a day in the morning. If necessary, after 3-4 weeks, the dose can be increased to 20 mg 2 times a day (morning and evening). The maximum daily dose is 80 mg 1-2 times a day.

Bulemic neurosis: up to 60 mg/day.

Intrusive disorders: 20-60 mg/day.

Symptoms: nausea, vomiting, anxiety, agitation, hypomania, seizures and other symptoms of CNS arousal.

Treatment: stomach washing, prescription of activated carbon, in convulsions - diazepam.

Careful monitoring of patients with suicidal tendencies is required, especially at the beginning of treatment. The risk of suicide is greatest in patients who have previously taken other antidepressants and patients who have excessive fatigue, hypersomnia or motor anxiety against the background of fluoxetine treatment.

When treating low-weight patients, the anorexygen properties of fluoxetine should be taken into account.

Prolonged epileptic seizures are possible with electroconvulsive therapy against the background of fluoxetine.

The interval between the cancellation of MAO inhibitors and the beginning of taking fluoxetine should be more than 2 weeks, and between the cancellation of fluoxetine and the intake of MAO inhibitors - at least 5 weeks.

Influence on the ability to drive vehicles and control mechanisms:

use with caution to drivers of vehicles and people whose activities require increased concentration and speed of psychomotor reactions. Alcohol should be avoided during treatment.

Capsules